Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
73 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cachexia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cachexia - Pipeline Review, H2 2014', provides an overview of the Cachexia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Cachexia Overview 8 Therapeutics Development 9 Pipeline Products for Cachexia - Overview 9 Pipeline Products for Cachexia - Comparative Analysis 10 Cachexia - Therapeutics under Development by Companies 11 Cachexia - Therapeutics under Investigation by Universities/Institutes 13 Cachexia - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Cachexia - Products under Development by Companies 16 Cachexia - Products under Investigation by Universities/Institutes 17 Cachexia - Companies Involved in Therapeutics Development 18 Plexxikon Inc. 18 BioLineRx, Ltd. 19 Neurocrine Biosciences, Inc. 20 Novartis AG 21 Aphios Corporation 22 Pfizer Inc. 23 Calzada Limited 24 Palatin Technologies, Inc. 25 Cytokinetics, Inc. 26 AVEO Pharmaceuticals, Inc. 27 Fountain Biopharma Inc. 28 Rhythm Pharmaceuticals 29 MI.TO. Technology S.r.L. 30 Cachexia - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 bimagrumab - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 PF-06260414 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 DLN-101 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 relamorelin - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 BL-5040 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 dronabinol - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 CK-2066260 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 PLX-4720 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 FB-704A - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 AV-380 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AOD-9604 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Drug for Cachexia - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Drugs to Inhibit Activin Receptor for Cachexia - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules to Modulate Melanocortin-4 Receptor for Cachexia - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cachexia - Recent Pipeline Updates 59 Cachexia - Dormant Projects 63 Cachexia - Discontinued Products 64 Cachexia - Product Development Milestones 65 Featured News & Press Releases 65 Apr 01, 2013: Cytokinetics Initiates Phase I Clinical Trial Of CK-2127107 65 Jan 03, 2013: Alize Pharma Launches PREMAG Research Program 65 Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix 66 Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 67 Jan 09, 2012: Ohr Pharmaceutical Receives US And European Composition Of Matter Patents 68 Sep 12, 2011: XBiotech Provides Early Results From True Human Antibody Therapy Clinical Study In Cachexia 68 Jul 20, 2011: Galapagos Initiates Proof-of-Mechanism Clinical Study Of Candidate Cachexia Drug GLPG0492 69 Dec 27, 2010: Vicus Initiates Phase II Trial To Evaluate VT-122 In Patients With Liver Cancer Receiving Nexavar 69 Dec 02, 2010: Galapagos Successfully Completes First-In-Human Trial Of GLPG0492 In Cachexia Patients 70 Jun 21, 2010: GTx Reports Ostarine Increased Lean Body Mass And Leg Press Strength In Head To Head Clinical Study 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 73 Disclaimer 73
List of Tables Number of Products under Development for Cachexia, H2 2014 9 Number of Products under Development for Cachexia - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Cachexia - Pipeline by Plexxikon Inc., H2 2014 18 Cachexia - Pipeline by BioLineRx, Ltd., H2 2014 19 Cachexia - Pipeline by Neurocrine Biosciences, Inc., H2 2014 20 Cachexia - Pipeline by Novartis AG, H2 2014 21 Cachexia - Pipeline by Aphios Corporation, H2 2014 22 Cachexia - Pipeline by Pfizer Inc., H2 2014 23 Cachexia - Pipeline by Calzada Limited, H2 2014 24 Cachexia - Pipeline by Palatin Technologies, Inc., H2 2014 25 Cachexia - Pipeline by Cytokinetics, Inc., H2 2014 26 Cachexia - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 27 Cachexia - Pipeline by Fountain Biopharma Inc., H2 2014 28 Cachexia - Pipeline by Rhythm Pharmaceuticals, H2 2014 29 Cachexia - Pipeline by MI.TO. Technology S.r.L., H2 2014 30 Assessment by Monotherapy Products, H2 2014 31 Number of Products by Stage and Target, H2 2014 33 Number of Products by Stage and Mechanism of Action, H2 2014 35 Number of Products by Stage and Route of Administration, H2 2014 37 Number of Products by Stage and Molecule Type, H2 2014 39 Cachexia Therapeutics - Recent Pipeline Updates, H2 2014 59 Cachexia - Dormant Projects, H2 2014 63 Cachexia - Discontinued Products, H2 2014 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
